Suppr超能文献

肺大细胞神经内分泌癌的分子亚型及预后因素

Molecular subtypes and prognostic factors of lung large cell neuroendocrine carcinoma.

作者信息

Liu Tingting, Chen Xueyuan, Mo Silang, Zhou Ting, Ma Wenjuan, Chen Gang, Chen Xiang, Shi Mengting, Yang Yuwen, Huang Yan, Zhao Hongyun, Fang Wenfeng, Yang Yunpeng, Li Jing, Zhang Li, Zhao Yuanyuan

机构信息

Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.

Department of Intensive Care Unit, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.

出版信息

Transl Lung Cancer Res. 2024 Sep 30;13(9):2222-2235. doi: 10.21037/tlcr-24-292. Epub 2024 Sep 27.

Abstract

BACKGROUND

Lung large cell neuroendocrine carcinoma (LCNEC) is an aggressive disease with poor prognosis and short-term survival, which lacks effective prognostic indicators. The study aims to investigate the molecular subtypes and prognostic markers of lung LCNEC.

METHODS

Patients diagnosed with lung LCNEC at Sun Yat-sen University Cancer Center (SYSUCC) between November 2007 and January 2021 were screened. Baseline clinical data were collected and routine blood indexes including lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and systemic immune-inflammation index (SII) were calculated. Immunohistochemistry (IHC) of ASCL1, NEUROD1, POU2F3, YAP1 were done to perform molecular subtyping, while CD56, Syn, CgA, CD3, CD8, CD20, CD68, and CD163 were also stained on tissue samples. Then prognostic factors of lung LCNEC were explored.

RESULTS

One hundred and fifty-one lung LCNEC patients were identified, 103 of whom had complete clinical information, available routine blood and biochemical indexes were eventually included in the present study. Tumor tissue specimens were available from 64 patients. Positive expression rates of ASCL1, NEUROD1, and YAP1 were 82.8%, 50.0%, and 28.1%, respectively. No POU2F3 cases were detected. Forty (62.5%) patients co-expressed with two or three markers. High LMR (>3.3) was an independent predictor of favorable prognosis of disease-free survival (DFS) [hazard ratio (HR), 0.391; 95% confidence interval (CI): 0.161-0.948; P=0.04] and overall survival (OS) (HR, 0.201; 95% CI: 0.071-0.574; P=0.003). Notably, high LMR was correlated with higher intra-tumoral CD3 (P=0.004), CD8 (P=0.01), and CD68 (P<0.001) immune cell infiltration compared to low LMR in lung LCNEC.

CONCLUSIONS

Our study validated molecular subtypes by IHC in lung LCNEC, and co-expression was found among different subtypes, with no prognostic effect. High blood LMR level was associated with a favorable prognosis in lung LCNEC, which might partly reflect a hot tumor tissue immune microenvironment. Our findings may benefit clinical practice, and further studies are warranted.

摘要

背景

肺大细胞神经内分泌癌(LCNEC)是一种侵袭性疾病,预后差,短期生存率低,缺乏有效的预后指标。本研究旨在探讨肺LCNEC的分子亚型和预后标志物。

方法

筛选2007年11月至2021年1月在中山大学肿瘤防治中心(SYSUCC)诊断为肺LCNEC的患者。收集基线临床资料,计算包括淋巴细胞与单核细胞比值(LMR)、中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)和全身免疫炎症指数(SII)在内的常规血液指标。进行ASCL1、NEUROD1、POU2F3、YAP1的免疫组织化学(IHC)检测以进行分子亚型分类,同时对组织样本进行CD56、Syn、CgA、CD3、CD8、CD20、CD68和CD163染色。然后探索肺LCNEC的预后因素。

结果

共纳入151例肺LCNEC患者,其中103例有完整的临床资料,最终将可用的常规血液和生化指标纳入本研究。64例患者有肿瘤组织标本。ASCL1、NEUROD1和YAP1的阳性表达率分别为82.8%、50.0%和28.1%。未检测到POU2F3阳性病例。40例(62.5%)患者共表达两种或三种标志物。高LMR(>3.3)是无病生存期(DFS)[风险比(HR),0.391;95%置信区间(CI):0.161 - 0.948;P = 0.04]和总生存期(OS)(HR,0.201;95%CI:0.071 - 0.574;P = 0.003)良好预后的独立预测因素。值得注意的是,与肺LCNEC中低LMR相比,高LMR与肿瘤内更高的CD3(P = 0.004)、CD8(P = 0.01)和CD68(P < 0.001)免疫细胞浸润相关。

结论

我们的研究通过IHC验证了肺LCNEC的分子亚型,发现不同亚型之间存在共表达,但无预后影响。高血液LMR水平与肺LCNEC的良好预后相关,这可能部分反映了肿瘤组织免疫微环境的活跃。我们的发现可能有益于临床实践,值得进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10d7/11484736/b299af9a23a5/tlcr-13-09-2222-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验